Prominent publications by Kenneth J Pienta

KOL Index score: 17882

CONTEXT: Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens.

OBJECTIVES: To determine the expression and clinical utility of alpha-methylacyl coenzyme A racemase (AMACR), a gene identified as being overexpressed in prostate cancer by global profiling strategies.

DESIGN: Four gene expression data sets from ...

Known for Prostate Cancer |  Tissue Biomarker |  Messenger Racemases |  Specificity Amacr |  Tumor Biopsy
KOL Index score: 16253

Resistance to cell death is a hallmark of cancer. Autophagy is a survival mechanism activated in response to nutrient deprivation; however, excessive autophagy will ultimately induce cell death in a nonapoptotic manner. The present study demonstrates that CCL2 protects prostate cancer PC3 cells from autophagic death, allowing prolonged survival in serum-free conditions. Upon serum starvation, CCL2 induced survivin up-regulation in PC3, DU 145, and C4-2B prostate cancer cells. Both cell ...

Known for Autophagic Death |  Pc3 Cells |  Phosphatidylinositol 3 |  Prostate Cancer |  Cell Survival
KOL Index score: 15981

It has been proposed that a 356 amino acid protein encoded by the MIM (Missing In Metastasis) gene on Chromosome 8q24.1, is a bladder cancer metastasis suppressor. Recently, Machesky and colleagues [Biochem. J. 371 (2003) 463] identified MIM-B, a 759 amino acid protein, of which the C-terminal 356 amino acids are almost identical to MIM. Importantly, PCR primers and Northern Blotting probes used in the studies of MIM in bladder cancer did not distinguish between sequences specific for ...

Known for Cell Lines |  Bladder Cancer |  Metastasis Suppressor |  Genetic Rna |  Neoplasm Proteins
KOL Index score: 15108

Cancer metastasis is a multistep process associated with the induction of an epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs). Although significant progress has been made in understanding the molecular mechanisms regulating EMT and the CSC phenotype, little is known of how these processes are regulated by epigenetics. Here we demonstrate that reduced expression of DNA methyltransferase 1 (DNMT1) plays an important role in the induction of EMT and the CSC phenotype by ...

Known for Cancer Metastasis |  Stem Cells |  Mesenchymal Transition |  Emt Dnmt1 |  Tumor Cell
KOL Index score: 15066

Antiapoptotic members of the Bcl-2 family proteins are overexpressed in prostate cancer and are promising molecular targets for modulating chemoresistance of prostate cancer. (-)-Gossypol, a natural BH3 mimetic, is a small-molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 currently in phase II clinical trials as an adjuvant therapy for human prostate cancer. Our objective is to examine the chemosensitization potential of (-)-gossypol in prostate cancer and its molecular mechanisms of action. ...

Known for Prostate Cancer |  Natural Bh3 Mimetic |  Bcl2 Proteins |  Antitumor Activity |  Noxa Puma
KOL Index score: 14890

At autopsy >or=80% of prostate cancers have established macrometastases in marrow containing bone. The mechanism(s) to explain this remarkable level of bone involvement remain to be elucidated. We examined the adhesive and invasive behavior of prostate cancer cells to osteoblastic and human bone marrow endothelial cells (HBME-1) in an attempt to explain the tropism of prostate cells for bone. We found an inverse relationship between adhesion and prostate cell tumorigenicity and ...

Known for Prostate Cancer |  Cells Bone |  Cell Adhesion |  C4 2 |  Marrow Endothelial
KOL Index score: 14839

Novel recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, or ETV4 have been recently identified as a common molecular event in prostate cancer development. We comprehensively analyzed the frequency and risk of disease progression for the TMPRSS2 and ETS family genes rearrangements in a cohort of 96 American men surgically treated for clinically localized prostate cancer. Using three break apart (TMPRSS2, ERG, ETV4) and one fusion ...

Known for Tmprss2 Erg |  Prostate Cancer |  Etv1 Etv4 |  Gene Aberrations |  Clinically Localized
KOL Index score: 14047

Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abiraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC). Here, we expanded our cohort size to better characterize the prognostic significance of AR-V7 in this setting. Methods We prospectively enrolled 202 patients with CRPC starting abiraterone or enzalutamide and ...

Known for Clinical Significance |  Messenger Receptors |  Ctc Arv7 |  Mrna Detection |  Circulating Tumor Cells
KOL Index score: 13144

To delineate the role of SDF-1 and CXCR4 in metastatic prostate cancer (CaP), positive correlations were established between SDF-1 levels and tumor metastasis. Neutralization of CXCR4 limited the number and the growth of intraosseous metastasis in vivo. Together, these in vivo metastasis data provide critical support that SDF-1/CXCR4 plays a role in skeletal metastasis.

INTRODUCTION: Previously we determined that the stromal-derived factor-1 (SDF-1)/CXCR4 chemokine axis is activated in ...

Known for Sdf1 Cxcr4 |  Prostate Cancer |  Messenger Receptors |  Metastasis Bone |  Cap Cells
KOL Index score: 13076

Prostate-specific membrane antigen (PSMA)-targeted PET imaging has become commonly used in patients with prostate cancer (PCa). The PSMA reporting and data system version 1.0 (PSMA-RADS version 1.0) categorizes lesions on the basis of the likelihood of PCa involvement, with PSMA-RADS-3A (soft-tissue) and PSMA-RADS-3B (bone) lesions being indeterminate for the presence of disease. We retrospectively reviewed the imaging follow-up of such lesions to determine the rate at which they ...

Known for Prostate Cancer |  Lesions Psma |  Pet Imaging |  Version 10 |  Retrospective Studies
KOL Index score: 12610

BACKGROUND: In virtually all patients with advanced prostate cancer, the disease metastasizes to bone and causes osteoblastic growth. However, the mechanisms that contribute to bone metastasis are poorly understood. It has been hypothesized that the bone provides a favorable growth environment for prostate cancer cells, which nonselectively seed the bone marrow from the bloodstream. Alternatively, prostate cancer cells may preferentially bind to bone marrow endothelial cells. We ...

Known for Prostate Cancer Cells |  Preferential Adhesion |  Endothelial Cell |  Bone Marrow |  Vitro Assay
KOL Index score: 12593

PURPOSE: To evaluate the combination of intravenous (IV) paclitaxel, oral estramustine, and oral etoposide in patients with advanced hormone-refractory prostate cancer.

PATIENTS AND METHODS: Forty patients with carcinoma of the prostate that was progressing despite hormonal therapy and who had undergone antiandrogen withdrawal (if previously treated with an antiandrogen) were enrolled onto this phase II trial. Patients were treated with oral estramustine 280 mg tid and oral etoposide 100 ...

Known for Oral Etoposide |  Patients Response |  Prostate Cancer |  Phase Trial |  Life Qol
KOL Index score: 12538

CCL2 is a cytokine prevalent in the prostate cancer tumor microenvironment. Recently, we reported that CCL2 induces the mammalian target of rapamycin (mTOR) pathway to promote prostate cancer PC3 cell survival; however, the mechanism used by CCL2 to maintain mTOR complex-1 (mTORC1) activation requires clarification. This study demonstrates that upon serum starvation, CCL2 functions as a negative regulator of AMP-activated protein kinase (AMPK) by decreasing phosphorylation at its major ...

Known for Cell Survival |  Survivin Expression |  Negative Regulator |  Activated Protein |  Cancer Pc3
KOL Index score: 12226

Epithelial-to-Mesenchymal Transition (EMT) and its reverse - Mesenchymal to Epithelial Transition (MET) - are hallmarks of cellular plasticity during embryonic development and cancer metastasis. During EMT, epithelial cells lose cell-cell adhesion and gain migratory and invasive traits either partially or completely, leading to a hybrid epithelial/mesenchymal (hybrid E/M) or a mesenchymal phenotype respectively. Mesenchymal cells move individually, but hybrid E/M cells migrate ...

Known for Mesenchymal Phenotype |  Hybrid Epithelial |  Partial Emt |  Tumor Cell |  Cancer Metastasis


Kenneth J Pienta: Influence Statistics

Sample of concepts for which Kenneth J Pienta is among the top experts in the world.
Concept World rank
grhl2 hybrid phenotype #1
ecm dht #1
prostate cancer systems #1
oral regimen estramustine #1
skeletal metastases cross #1
oligoprogressive crpc mdt #1
detrusor mechanical stimulus #1
pdc cells imc #1
wtimc p50imc #1
data mcrps #1
survival prolongation prlt #1
reticulocalbin rcn1 #1
tams key components #1
heritable variation conditions #1
game theory cancer #1
response serum psa #1
cov organ #1
continuous tension cables #1
cell actin matrix #1
node metastases chinese #1
adapted equations equations #1
409nr #1
academy meeting #1
traces tumor features #1
liquid biopsy bca #1
lpfs bpfs #1
controls psa decline #1
rcn1 cell surface #1
unrecognized actuators #1
cytokines dht #1
cooperation cancer cells #1
efferocytosis receptors #1
rcn1 pca #1
efficacy angiogenesis inhibitors #1
murine prostate micro #1
tissue tensegritymatrix #1
mechanism tumor inhibition #1
ccl2 humans #1
mibc ctcs #1
cd55 prostate cancer #1
discussions 2017 chpca #1
expression mim #1
β1 rac1 #1
recurrence modes #1
ccl2 tumor growth #1
nuclear matrix humans #1
emp nuclear matrix #1
studies gossypol #1
work annexin #1
common kinases #1

Key People For Prostate Cancer

Top KOLs in the world
Ahmedin M Jemal
united states breast cancer addis ababa
Peter T Scardino
prostate cancer active surveillance erectile function
Rebecca L Siegel
united states colorectal cancer incidence rates
Johnathan I Jonathan
prostate cancer gleason score needle biopsy
Philip W Kantoff
prostate cancer psma adc androgen deprivation therapy
prostate cancer specific antigen pathological stage

Kenneth J Pienta:Expert Impact

Concepts for whichKenneth J Pientahas direct influence:Prostate cancer,  Cancer cells,  Nuclear matrix,  Tumor cells,  Cancer cell,  Bone marrow,  Prostate cancer cells,  Metastatic prostate cancer.

Kenneth J Pienta:KOL impact

Concepts related to the work of other authors for whichfor which Kenneth J Pienta has influence:Prostate cancer,  Tumor cells,  Gene expression,  Androgen receptor,  Cell proliferation,  Prostatic neoplasms,  Bone metastasis.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, | Cellular and Molecular Medicine Program, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA;,

FREE Custom List